OVERSEA CHINESE BANKING Corp Ltd Lowers Position in Illumina, Inc. $ILMN

OVERSEA CHINESE BANKING Corp Ltd lessened its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 9.3% in the 4th quarter, HoldingsChannel.com reports. The firm owned 272,920 shares of the life sciences company’s stock after selling 28,001 shares during the period. Illumina accounts for 0.9% of OVERSEA CHINESE BANKING Corp Ltd’s holdings, making the stock its 23rd biggest position. OVERSEA CHINESE BANKING Corp Ltd’s holdings in Illumina were worth $35,796,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Capital World Investors raised its stake in shares of Illumina by 20.0% in the third quarter. Capital World Investors now owns 19,976,850 shares of the life sciences company’s stock worth $1,897,178,000 after buying an additional 3,331,542 shares during the period. State Street Corp grew its stake in shares of Illumina by 6.8% during the 3rd quarter. State Street Corp now owns 5,999,790 shares of the life sciences company’s stock valued at $569,800,000 after acquiring an additional 382,520 shares during the period. AQR Capital Management LLC increased its holdings in Illumina by 3.1% in the 3rd quarter. AQR Capital Management LLC now owns 3,398,027 shares of the life sciences company’s stock worth $315,915,000 after acquiring an additional 102,147 shares in the last quarter. Bank of America Corp DE increased its holdings in Illumina by 1.9% in the 2nd quarter. Bank of America Corp DE now owns 1,930,843 shares of the life sciences company’s stock worth $184,222,000 after acquiring an additional 35,167 shares in the last quarter. Finally, ARK Investment Management LLC raised its stake in Illumina by 25.7% during the 3rd quarter. ARK Investment Management LLC now owns 1,467,879 shares of the life sciences company’s stock worth $139,405,000 after acquiring an additional 299,801 shares during the period. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have weighed in on ILMN shares. TD Cowen reaffirmed a “hold” rating on shares of Illumina in a report on Wednesday, January 7th. Stifel Nicolaus increased their price objective on shares of Illumina from $135.00 to $155.00 and gave the stock a “buy” rating in a research note on Tuesday, January 20th. UBS Group restated a “neutral” rating and set a $135.00 price objective on shares of Illumina in a research report on Friday, February 6th. Canaccord Genuity Group lifted their target price on shares of Illumina from $130.00 to $150.00 and gave the company a “hold” rating in a research note on Monday, January 26th. Finally, Robert W. Baird set a $137.00 target price on shares of Illumina in a report on Friday, February 6th. Six analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $129.69.

Illumina Price Performance

ILMN stock opened at $131.98 on Wednesday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.72 and a current ratio of 2.08. The company’s fifty day moving average price is $124.37 and its 200-day moving average price is $125.39. Illumina, Inc. has a one year low of $72.72 and a one year high of $155.53. The company has a market capitalization of $20.05 billion, a PE ratio of 24.22, a price-to-earnings-growth ratio of 2.55 and a beta of 1.49.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, February 5th. The life sciences company reported $1.35 earnings per share for the quarter, beating the consensus estimate of $1.26 by $0.09. The company had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.10 billion. Illumina had a net margin of 19.57% and a return on equity of 31.04%. Illumina’s quarterly revenue was up 5.0% on a year-over-year basis. During the same period last year, the company posted $0.95 earnings per share. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. On average, equities analysts anticipate that Illumina, Inc. will post 5.12 EPS for the current fiscal year.

Insider Buying and Selling at Illumina

In other news, SVP Patricia Leckman sold 2,370 shares of the firm’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total transaction of $275,346.60. Following the completion of the transaction, the senior vice president owned 16,321 shares in the company, valued at $1,896,173.78. This trade represents a 12.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 0.17% of the stock is currently owned by insiders.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.